These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21939764)

  • 1. Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women.
    Straume AH; Knappskog S; Lønning PE
    J Steroid Biochem Mol Biol; 2012 Jan; 128(1-2):69-75. PubMed ID: 21939764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP19 (aromatase) haplotypes and endometrial cancer risk.
    Paynter RA; Hankinson SE; Colditz GA; Kraft P; Hunter DJ; De Vivo I
    Int J Cancer; 2005 Aug; 116(2):267-74. PubMed ID: 15800924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.
    Wang L; Ellsworth KA; Moon I; Pelleymounter LL; Eckloff BW; Martin YN; Fridley BL; Jenkins GD; Batzler A; Suman VJ; Ravi S; Dixon JM; Miller WR; Wieben ED; Buzdar A; Weinshilboum RM; Ingle JN
    Cancer Res; 2010 Jan; 70(1):319-28. PubMed ID: 20048079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk.
    Talbott KE; Gammon MD; Kibriya MG; Chen Y; Teitelbaum SL; Long CM; Gurvich I; Santella RM; Ahsan H
    Breast Cancer Res Treat; 2008 Oct; 111(3):481-7. PubMed ID: 17975727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.
    Geisler J; Haynes B; Ekse D; Dowsett M; Lønning PE
    J Steroid Biochem Mol Biol; 2007 Apr; 104(1-2):27-34. PubMed ID: 17350249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk.
    Haiman CA; Hankinson SE; Spiegelman D; De Vivo I; Colditz GA; Willett WC; Speizer FE; Hunter DJ
    Int J Cancer; 2000 Jul; 87(2):204-10. PubMed ID: 10861475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.
    Haiman CA; Dossus L; Setiawan VW; Stram DO; Dunning AM; Thomas G; Thun MJ; Albanes D; Altshuler D; Ardanaz E; Boeing H; Buring J; Burtt N; Calle EE; Chanock S; Clavel-Chapelon F; Colditz GA; Cox DG; Feigelson HS; Hankinson SE; Hayes RB; Henderson BE; Hirschhorn JN; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Le Marchand L; Lenner P; Lund E; Panico S; Peeters PH; Pike MC; Riboli E; Tjonneland A; Travis R; Trichopoulos D; Wacholder S; Ziegler RG
    Cancer Res; 2007 Mar; 67(5):1893-7. PubMed ID: 17325027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort.
    Haiman CA; Stram DO; Pike MC; Kolonel LN; Burtt NP; Altshuler D; Hirschhorn J; Henderson BE
    Hum Mol Genet; 2003 Oct; 12(20):2679-92. PubMed ID: 12944421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
    Salhab M; Reed MJ; Al Sarakbi W; Jiang WG; Mokbel K
    Breast Cancer Res Treat; 2006 Sep; 99(2):155-62. PubMed ID: 16541304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase and breast cancer susceptibility.
    Probst-Hensch NM; Ingles SA; Diep AT; Haile RW; Stanczyk FZ; Kolonel LN; Henderson BE
    Endocr Relat Cancer; 1999 Jun; 6(2):165-73. PubMed ID: 10731105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Lønning PE; Haynes BP; Dowsett M
    Eur J Cancer; 2014 Apr; 50(6):1055-64. PubMed ID: 24507547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status.
    Geisler J; Suzuki T; Helle H; Miki Y; Nagasaki S; Duong NK; Ekse D; Aas T; Evans DB; Lønning PE; Sasano H
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):237-41. PubMed ID: 19883757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches.
    Olson JE; Ingle JN; Ma CX; Pelleymounter LL; Schaid DJ; Pankratz VS; Vierkant RA; Fredericksen ZS; Wu Y; Couch FJ; Vachon CM; Sellers TA; Weinshilboum RM
    Breast Cancer Res Treat; 2007 Apr; 102(2):237-47. PubMed ID: 17004113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variants of CYP19 (aromatase) and breast cancer risk.
    Kristensen VN; Harada N; Yoshimura N; Haraldsen E; Lonning PE; Erikstein B; Kåresen R; Kristensen T; Børresen-Dale AL
    Oncogene; 2000 Mar; 19(10):1329-33. PubMed ID: 10713674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sources of estrogen and their importance.
    Simpson ER
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):225-30. PubMed ID: 14623515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic mechanisms regulating CYP19 transcription in human breast adipose fibroblasts.
    Knower KC; To SQ; Simpson ER; Clyne CD
    Mol Cell Endocrinol; 2010 Jun; 321(2):123-30. PubMed ID: 20211687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers.
    Huang CS; Kuo SH; Lien HC; Yang SY; You SL; Shen CY; Lin CH; Lu YS; Chang KJ
    Oncologist; 2008 Jul; 13(7):751-60. PubMed ID: 18614591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.
    Raskin L; Lejbkowicz F; Barnett-Griness O; Dishon S; Almog R; Rennert G
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1617-23. PubMed ID: 19366906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women.
    Zhang L; Gu L; Qian B; Hao X; Zhang W; Wei Q; Chen K
    Breast Cancer Res Treat; 2009 Mar; 114(2):327-38. PubMed ID: 18629629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis.
    Riancho JA; Valero C; Naranjo A; Morales DJ; Sañudo C; Zarrabeitia MT
    J Clin Endocrinol Metab; 2007 Feb; 92(2):660-5. PubMed ID: 17118999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.